Trials / Active Not Recruiting
Active Not RecruitingNCT00600496
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies
Conditions
- Breast Cancer
- Breast Neoplasms
- Colon Cancer
- Colonic Cancer
- Colon Neoplasms
- Lung Cancer
- Melanoma
- Kidney Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6244 | twice daily oral dose |
| DRUG | Dacarbazine | intravenous infusion |
| DRUG | Erlotinib | daily oral dose |
| DRUG | Docetaxel | intravenous infusion |
| DRUG | Temsirolimus | intravenous infusion |
Timeline
- Start date
- 2007-12-14
- Primary completion
- 2010-08-20
- Completion
- 2025-12-31
- First posted
- 2008-01-25
- Last updated
- 2025-11-13
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00600496. Inclusion in this directory is not an endorsement.